RYBREVANT FASPRO IS NOW APPROVED

For adults with head and neck cancer that has spread to other parts of the body (metastatic) or has come back whose disease has worsened on or after platinum-based chemotherapy and an anti–PD-(L)1 immunotherapy

Not for use to treat people with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated.

RYBREVANT FASPRO is approved based on treatment response and how long the response lasted. Continued approval may depend on future studies that confirm its benefits.

HPV, human papillomavirus; PD-(L)1, programmed cell death (ligand) protein 1.

AI-generated image. Not an actual patient.

Once you and your doctor
have decided that a
RYBREVANT FASPRO–based
treatment is right for you, sign up for:

Dedicated support

Starting a new treatment can be overwhelming and you may still have questions. We are here to help. Sign up for RYBREVANT withMe.

Learn more

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Start treatment with confidence

Sign up for a RYBREVANT FASPRO Starter Kit, as well as other support and communications, to help you get started and continue your treatment journey.